30.43
-1.02 (-3.24%)
| Penutupan Terdahulu | 31.45 |
| Buka | 31.53 |
| Jumlah Dagangan | 1,157,260 |
| Purata Dagangan (3B) | 1,351,398 |
| Modal Pasaran | 2,904,300,288 |
| Harga / Jualan (P/S) | 36.74 |
| Harga / Buku (P/B) | 9.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -130,369.45% |
| EPS Cair (TTM) | -3.35 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.82% |
| Nisbah Semasa (MRQ) | 19.49 |
| Aliran Tunai Operasi (OCF TTM) | -279.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -171.41 M |
| Pulangan Atas Aset (ROA TTM) | -32.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Viridian Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 4.0 |
| Purata | 2.25 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.16% |
| % Dimiliki oleh Institusi | 114.61% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Maverick Capital Ltd | 30 Sep 2025 | 2,212,701 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 61.00 (BTIG, 100.46%) | Beli |
| Median | 43.00 (41.31%) | |
| Rendah | 36.00 (Oppenheimer, 18.30%) | Beli |
| Purata | 45.75 (50.35%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 26.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 24 Nov 2025 | 41.00 (34.74%) | Beli | 32.03 |
| RBC Capital | 06 Nov 2025 | 45.00 (47.88%) | Beli | 27.50 |
| BTIG | 04 Nov 2025 | 61.00 (100.46%) | Beli | 22.55 |
| Oppenheimer | 21 Oct 2025 | 36.00 (18.30%) | Beli | 24.02 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |